A further mechanism of action has proven ineffective in top-line data from a late-stage study in Alzheimer's disease, adding to the long list of tried and failed approaches to the seemingly intractable condition.

Huntington's disease is one of several genetically defined neurological diseases that are being targeted in a multibillion-dollar collaboration forged between the US's Wave Life Sciences and Japan's Takeda, that could include co-commercialization by the biotech in the US.

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

The TOMMORROW study was revolutionary for its time in testing Actos early, before symptoms are apparent; failure is disappointing but similar metabolic approaches might still play a role, says the Alzheimer's Association.